Compared with standard platinum-based chemotherapy doublets, EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib show more pronounced antitumor effects in NSCLC patients who harbor such activating EGFR mutations, which include in-frame deletions in exon 19 and an L858R point mutation in exon 21 [2–5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.